Table 2.

The effect of the V-ATPase inhibitors, bafilomycin A1 (BAF) and concanamycin A (CCA), on cytokine-dependent proliferation of primary human AML cells; a summary of the overall results. Eighty patients were tested in the ³H-thymidin incorporation assay; seventy of them showed detectable proliferation corresponding to ³H-thymidine incorporation > 1000 cpm in the drug-free controls. The table presents a summary of the results for these 70 patients with detectable cytokine-dependent proliferation. The left part of the table presents the results as the nuclear incorporation of ³H-thymidine (counts per minute, cpm) together with the results from the statistical analysis, whereas the right part of the table presents the results as the relative responses, i.e., the nuclear radioactivity for drug-containing cultures relative to the nuclear radioactivity in the corresponding drug-free control cultures. The Wilcoxon’s test for paired samples was used for all statistical comparisons, and the median cpm of triplicate cultures was used for all calculations and statistical comparisons (nd/not detectable proliferation).

Drugs Added	Proliferation in Drug-Free Controls and in Drug-Containing Cultures (cpm)			Proliferation in Drug-Containing Relative to Proliferation in Corresponding Drug-Free Controls (Relative Response)
	Median	Range	p-Value	Median	Range
Drug-free control	11,683	1317–173,197		1.00	-
BAF 10 nM	3177	nd-81,388	<0.0005	0.30	0.03–1.30
BAF 5 nM	7208	nd-137,101	<0.0005	0.82	0.19–1.40
BAF 1 nM	11,505	nd-161,956	0.001	0.96	0.52–1.25
CCA 10 nM	<1000 cpm	<1000 cpm	<0.0005	0.09	0.01–0.98
CCA 5 nM	<1000 cpm	<1000 cpm	<0.0005	0.9	0.01–0.98
CCA 1 nM	<1000 cpm	<1000 cpm-66,606	<0.0005	0.13	0.01–1.74